Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial
Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sanofi and Regeneron are running a proof-of-concept Phase 2 trial called “A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis.” The study tests whether their antibody drug can help adults with chronic lung damage that causes frequent cough and infections.
The treatment is itepekimab, also known as SAR440340 or REGN3500, given as an injection under the skin. It is designed to block IL-33, a signal in the immune system that may drive inflammation in the lungs of patients with non-cystic fibrosis bronchiectasis.
The trial is interventional and randomized, meaning patients are assigned by chance to drug or placebo groups. It is triple-blinded, so patients, doctors and study staff do not know who gets itepekimab or placebo, and the main goal is to see if the drug helps treat disease symptoms safely.
Participants are split into three groups that run in parallel. One group gets itepekimab every two weeks, one gets it every four weeks with placebo in between, and one receives placebo injections every two weeks, all for up to 52 weeks followed by a safety check.
The study includes a screening phase, 24–52 weeks of treatment and a 20-week safety follow-up, for a total of up to 47–77 weeks per patient. Regular visits, either in person or by phone, occur about once a month to track safety, lung health and any side effects.
The trial status is listed as Completed, showing all patients have finished treatment and follow-up. The study was first submitted on Feb. 20, 2024, and the most recent update was posted on Feb. 9, 2026, which signals that data review or preparation for public release is ongoing.
For investors, a completed Phase 2 proof-of-concept trial in bronchiectasis adds optionality to both Sanofi and Regeneron beyond their current asthma and allergy portfolios. If results are positive, it could open a new niche respiratory market where options are limited and support a premium for REGN and SNYNF on growth expectations.
Competitive pressure in respiratory care comes from firms like GSK and AstraZeneca, but few have strong assets in non-cystic fibrosis bronchiectasis, so a clear signal of benefit could be meaningful. Conversely, weak or mixed data could slightly weigh on sentiment, as investors may reassess the value of itepekimab within each company’s broader pipeline.
The study is now completed but was recently updated, and further details and future milestones will be available on the ClinicalTrials portal.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.
